
Evommune Shares Positive Phase 2a Top-Line Data for EVO301 in Atopic Dermatitis
Evommune Announces Positive Top-line Data from Phase 2a Proof-of-Concept Trial of EVO301 in Moderate-to-Severe Atopic Dermatitis Evommune, Inc. a clinical-stage biotechnology company developing innovative therapies that target key drivers of…












